Cargando…
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
Post-marketing reporting of adverse drug events is essential for new medications, as pre-FDA approval studies lack sufficient subject numbers to detect signals for rare events. Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equaled or excee...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916542/ https://www.ncbi.nlm.nih.gov/pubmed/29707095 http://dx.doi.org/10.14740/jocmr3394w |